Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 246

1.

Efficacy of flutamide-combined androgen blockade therapy in advanced prostate cancer patients: a phase III randomized, comparative trial.

Kanetake H, Usami M, Ohashi Y, Ijima T, Akaza H.

Gan To Kagaku Ryoho. 2014 Dec;41(13):2591-7.

PMID:
25596054
2.

Assessment of lower urinary tract function in children with Down syndrome.

Kitamura A, Kondoh T, Noguchi M, Hatada T, Tohbu S, Mori KI, Matsuo M, Kunitsugu I, Kanetake H, Moriuchi H.

Pediatr Int. 2014 Dec;56(6):902-908. doi: 10.1111/ped.12367. Epub 2014 Oct 15.

3.

Renoprotective effects of telmisartan after unilateral renal ablation in rats.

Matsuo T, Miyata Y, Sagara Y, Higami Y, Tobu S, Matsuo M, Noguchi M, Shimokawa I, Kanetake H, Sakai H.

Int J Nephrol Renovasc Dis. 2013 Oct 10;6:207-14. doi: 10.2147/IJNRD.S51216. eCollection 2013.

4.

Semen quality of 1559 young men from four cities in Japan: a cross-sectional population-based study.

Iwamoto T, Nozawa S, Mieno MN, Yamakawa K, Baba K, Yoshiike M, Namiki M, Koh E, Kanaya J, Okuyama A, Matsumiya K, Tsujimura A, Kanetake H, Eguchi J, Skakkebaek NE, Vierula M, Toppari J, Jørgensen N.

BMJ Open. 2013 Apr 29;3(4). pii: e002222. doi: 10.1136/bmjopen-2012-002222. Print 2013.

5.

Tumor-associated stromal cells expressing E-prostanoid 2 or 3 receptors in prostate cancer: correlation with tumor aggressiveness and outcome by angiogenesis and lymphangiogenesis.

Miyata Y, Ohba K, Matsuo T, Watanabe S, Hayashi T, Sakai H, Kanetake H.

Urology. 2013 Jan;81(1):136-42. doi: 10.1016/j.urology.2012.08.014. Epub 2012 Nov 11.

PMID:
23149328
6.
7.

Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.

Miyata Y, Nomata K, Ohba K, Matsuo T, Sagara Y, Kanetake H, Sakai H.

Cancer Chemother Pharmacol. 2012 Sep;70(3):451-9. doi: 10.1007/s00280-012-1938-3. Epub 2012 Aug 3.

8.

Response of recurrent urachal cancer to gemcitabine and cisplatin therapy: a case report and literature review.

Miyata Y, Sagara Y, Matsuo T, Ohba K, Takahashi H, Sakai H, Kanetake H.

Anticancer Res. 2011 Jun;31(6):2335-8.

PMID:
21737660
9.

Clinical significance and predictive value of prostaglandin E2 receptors (EPR) 1 - 4 in patients with renal cell carcinoma.

Ohba K, Miyata Y, Watanabe S, Hayashi T, Kanetake H, Kanda S, Sakai H.

Anticancer Res. 2011 Feb;31(2):597-605.

PMID:
21378344
10.

[Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].

Sakai H, Igawa T, Onita T, Furukawa M, Hakariya T, Hayashi M, Matsuya F, Shida Y, Nishimura N, Yogi Y, Tsurusaki T, Takehara K, Nomata K, Shiraishi K, Shono T, Aoki D, Kanetake H.

Hinyokika Kiyo. 2011 Jan;57(1):7-13. Japanese.

11.

Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study.

Akaza H, Kanetake H, Tsukamoto T, Miyanaga N, Sakai H, Masumori N, Nakatsu H, Sagiyama K, Sakamoto S, Endo Y, Yamanouchi T; REDUCE Study Group.

Jpn J Clin Oncol. 2011 Mar;41(3):417-23. doi: 10.1093/jjco/hyq221. Epub 2010 Dec 1.

PMID:
21123311
12.

Expression of matrix metalloproteinase-10 in non-metastatic prostate cancer: Correlation with an imbalance in cell proliferation and apoptosis.

Maruta S, Miyata Y, Sagara Y, Kanda S, Iwata T, Watanabe SI, Sakai H, Hayashi T, Kanetake H.

Oncol Lett. 2010 May;1(3):417-421. Epub 2010 May 1.

13.

Green tea polyphenol suppresses tumor invasion and angiogenesis in N-butyl-(-4-hydroxybutyl) nitrosamine-induced bladder cancer.

Sagara Y, Miyata Y, Nomata K, Hayashi T, Kanetake H.

Cancer Epidemiol. 2010 Jun;34(3):350-4. doi: 10.1016/j.canep.2010.03.001. Epub 2010 Apr 1.

PMID:
20362526
14.

Human papillomavirus genotypes in penile cancers from Japanese patients and HPV-induced NF-κB activation.

Senba M, Mori N, Wada A, Fujita S, Yasunami M, Irie S, Hayashi T, Igawa T, Kanetake H, Takahara O, Toriyama K.

Oncol Lett. 2010 Mar;1(2):267-272. Epub 2010 Mar 1.

15.

Clinical significance and prognostic value of S100A4 and matrix metalloproteinase-14 in patients with organ-confined bladder cancer.

Sagara Y, Miyata Y, Iwata T, Kanda S, Hayashi T, Sakai H, Kanetake H.

Exp Ther Med. 2010 Jan;1(1):27-31. Epub 2010 Jan 1.

16.

Expression of X-linked inhibitor of apoptosis protein in human prostate cancer specimens with and without neo-adjuvant hormonal therapy.

Watanabe S, Miyata Y, Kanda S, Iwata T, Hayashi T, Kanetake H, Sakai H.

J Cancer Res Clin Oncol. 2010 May;136(5):787-93. doi: 10.1007/s00432-009-0718-x. Epub 2009 Nov 28.

PMID:
19946707
17.

[Secondary endocrine therapy with oral estrogen for relapsed prostate cancer].

Onita T, Igawa T, Hisamatsu H, Sakai H, Kanetake H.

Hinyokika Kiyo. 2009 Oct;55(10):595-8. Japanese.

18.

E1AF expression is associated with extra-prostatic growth and matrix metalloproteinase-7 expression in prostate cancer.

Maruta S, Sakai H, Kanda S, Hayashi T, Kanetake H, Miyata Y.

APMIS. 2009 Nov;117(11):791-6. doi: 10.1111/j.1600-0463.2009.02534.x.

PMID:
19845529
19.

Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.

Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y; Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer.

Cancer. 2009 Aug 1;115(15):3437-45. doi: 10.1002/cncr.24395.

20.

Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.

Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H.

Hum Pathol. 2009 Apr;40(4):496-504. doi: 10.1016/j.humpath.2008.09.011. Epub 2009 Jan 3.

PMID:
19121849
21.
22.

Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.

Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H.

Urology. 2009 Mar;73(3):635-40. doi: 10.1016/j.urology.2008.09.013. Epub 2008 Nov 26.

PMID:
19038426
23.

TFE3-renal carcinoma in an adult patient: a case with strong expression of phosphorylated hepatocyte growth factor (HGFR)/Met.

Sagara Y, Miyata Y, Nomata K, Abe K, Eguchi J, Hayashi T, Sakai H, Kanda S, Kanetake H.

Pathol Res Pract. 2009;205(1):57-61. doi: 10.1016/j.prp.2008.08.001. Epub 2008 Oct 17.

PMID:
18930356
24.

Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells.

Kanda S, Kanetake H, Miyata Y.

J Cancer Res Clin Oncol. 2009 Feb;135(2):303-11. doi: 10.1007/s00432-008-0465-4. Epub 2008 Aug 23.

PMID:
18726116
25.

Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.

Arai Y, Akaza H, Deguchi T, Fujisawa M, Hayashi M, Hirao Y, Kanetake H, Naito S, Namiki M, Tachibana M, Usami M, Ohashi Y.

J Cancer Res Clin Oncol. 2008 Dec;134(12):1385-96. doi: 10.1007/s00432-008-0409-z. Epub 2008 May 20.

PMID:
18491137
26.

Lymphangiogenesis and angiogenesis in conventional renal cell carcinoma: association with vascular endothelial growth factors A to D immunohistochemistry.

Iwata T, Miyata Y, Kanda S, Nishikido M, Hayashi T, Sakai H, Kanetake H.

Urology. 2008 Apr;71(4):749-54. doi: 10.1016/j.urology.2007.10.063. Epub 2008 Mar 4.

PMID:
18295862
27.

Long-term exposure of human renal carcinoma cells to PD98059 induces epithelial-mesenchymal transition-like phenotype and enhanced motility.

Kanda S, Kanetake H, Miyata Y.

Mol Cell Biochem. 2008 Feb;309(1-2):69-76. Epub 2007 Nov 14.

PMID:
18000741
28.

Immunohistochemical analysis of connexin43 expression in infertile human testes.

Matsuo Y, Nomata K, Eguchi J, Aoki D, Hayashi T, Hishikawa Y, Kanetake H, Shibata Y, Koji T.

Acta Histochem Cytochem. 2007 Jul 3;40(3):69-75.

29.
30.

Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review).

Kanda S, Miyata Y, Kanetake H, Smithgall TE.

Int J Mol Med. 2007 Jul;20(1):113-21. Review.

PMID:
17549397
31.
32.

[Cost-effectiveness analysis of maximum androgen blockade for Japanese men with advanced prostate cancer].

Nishimura S, Arai Y, Usami M, Kanetake H, Naito S, Akaza H.

Gan To Kagaku Ryoho. 2007 Apr;34(4):589-95. Japanese.

PMID:
17431346
33.

Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role.

Miyata Y, Iwata T, Maruta S, Kanda S, Nishikido M, Koga S, Kanetake H.

Eur Urol. 2007 Sep;52(3):791-7. Epub 2006 Dec 26.

PMID:
17207914
34.

Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.

Usami M, Akaza H, Arai Y, Hirano Y, Kagawa S, Kanetake H, Naito S, Sumiyoshi Y, Takimoto Y, Terai A, Yoshida H, Ohashi Y.

Prostate Cancer Prostatic Dis. 2007;10(2):194-201. Epub 2007 Jan 2.

PMID:
17199134
35.

p38MAPK activation is involved in androgen-independent proliferation of human prostate cancer cells by regulating IL-6 secretion.

Shida Y, Igawa T, Hakariya T, Sakai H, Kanetake H.

Biochem Biophys Res Commun. 2007 Feb 16;353(3):744-9. Epub 2006 Dec 20.

PMID:
17196171
36.

Relationship between prostaglandin E2 receptors and clinicopathologic features in human prostate cancer tissue.

Miyata Y, Kanda S, Maruta S, Matsuo T, Sakai H, Hayashi T, Kanetake H.

Urology. 2006 Dec;68(6):1360-5.

PMID:
17169665
38.

A questionnaire survey of patient preparation and techniques for prostate biopsy among urologists in the Kyushu and Okinawa regions of Japan.

Noguchi M, Matsuoka K, Koga H, Kanetake H, Nakagawa M, Naito S.

Int J Clin Oncol. 2006 Oct;11(5):390-5.

PMID:
17058137
39.

[A case of metastatic tumor of spermatic cord from ascending colon carcinoma].

Shida Y, Miyata Y, Igawa T, Sakai H, Koga S, Kanetake H.

Hinyokika Kiyo. 2006 Sep;52(9):733-5. Japanese.

40.
41.

Calreticulin represses E-cadherin gene expression in Madin-Darby canine kidney cells via Slug.

Hayashida Y, Urata Y, Muroi E, Kono T, Miyata Y, Nomata K, Kanetake H, Kondo T, Ihara Y.

J Biol Chem. 2006 Oct 27;281(43):32469-84. Epub 2006 Aug 30.

43.

Fibroblast growth factor-2 induces the activation of Src through Fes, which regulates focal adhesion disassembly.

Kanda S, Miyata Y, Kanetake H, Smithgall TE.

Exp Cell Res. 2006 Oct 1;312(16):3015-22. Epub 2006 Jul 1.

PMID:
16884713
44.

Tumor lymphangiogenesis in transitional cell carcinoma of the upper urinary tract: association with clinicopathological features and prognosis.

Miyata Y, Kanda S, Ohba K, Nomata K, Eguchi J, Hayashida Y, Kanetake H.

J Urol. 2006 Jul;176(1):348-53.

PMID:
16753442
45.

Elevated expression of ERK 2 in human tumor cells chronically treated with PD98059.

Kanda S, Kanetake H, Miyata Y.

Biochem Biophys Res Commun. 2006 Jul 14;345(4):1481-6. Epub 2006 May 15.

PMID:
16729971
46.

Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.

Kanda S, Miyata Y, Kanetake H.

Int J Clin Oncol. 2006 Apr;11(2):90-107. Review.

PMID:
16622744
47.

HGF-induced capillary morphogenesis of endothelial cells is regulated by Src.

Kanda S, Kanetake H, Miyata Y.

Biochem Biophys Res Commun. 2006 Jun 2;344(2):617-22. Epub 2006 Apr 6.

PMID:
16620780
48.

Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract.

Miyata Y, Ohba K, Kanda S, Nomata K, Eguchi J, Hayashi T, Kanetake H.

Virchows Arch. 2006 Jun;448(6):822-9. Epub 2006 Apr 12.

PMID:
16609907
49.

Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis.

Kinouchi T, Sakamoto J, Tsukamoto T, Akaza H, Kubota Y, Ozono S, Kanetake H, Taguchi T, Kotake T; Immunotherapy Oncology Group for Renal Cell Carcinoma.

J Cancer Res Clin Oncol. 2006 Aug;132(8):499-504. Epub 2006 Apr 4.

PMID:
16586071
50.

Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.

Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, Shinohara N, Shinka T, Tachibana M, Naito S, Hirao Y; BCG Tokyo 172 Strain Study Group.

Urology. 2006 Mar;67(3):545-9.

PMID:
16527576

Supplemental Content

Loading ...
Support Center